• 1
    Ibrahim EM, Zeeneldin AA, Sadiq BB, Ezzat AA. The present and the future of breast cancer burden in the Kingdom of Saudi Arabia. Med Oncol 2008;25:38793.
  • 2
    Ravichandran K, Al-Zahrani AS. Association of reproductive factors with the incidence of breast cancer in Gulf Cooperation Council countries. East Mediterr Health J 2009;15:61221.
  • 3
    Abulkhair O, Saghir N, Sedky L, Saadedin A, Elzahwary H, Siddiqui N et al. Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region. J Natl Compr Canc Netw 2011;8:S815.
  • 4
    Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi CA. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. Am Rev Respir Dis 1993;147:126470.
  • 5
    Partridge AH, Burstein HJ, Winer EP. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr 2001;30:13542.
  • 6
    Yagata H, Kajiura Y, Yamauchi H. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer 2011;18:16573.
  • 7
    Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 2008;19:184752.
  • 8
    Kim MH, Chung J. Synergistic cell death by EGCG and ibuprofen in DU-145 prostate cancer cell line. Anticancer Res 2007;27:394756.
  • 9
    Phillips HA. The role of the p53 tumour suppressor gene in human breast cancer. Clin Oncol 1999;11:14855.
  • 10
    Lim LY, Vidnovic N, Ellisen LW, Leong CO. Mutant p53 mediates survival of breast cancer cells. Br J Cancer 2009;101:160612.
  • 11
    Achanta G, Huang P. Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res 2004;64:62339.
  • 12
    Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated p38alpha MAPK activation through ROS generation. Apoptosis 2007;12:173342.
  • 13
    Basma H, El-Refaey H, Sgagias MK, Cowan KH, Luo X, Cheng PW. Bcl-2 antisense and cisplatin combination treatment of MCF-7 breast cancer cells with or without functional p53. J Biomed Sci 2005;12:9991011.
  • 14
    Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, Reed JC et al. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 2000;60:438690.
  • 15
    Macip S, Igarashi M, Berggren P, Yu J, Lee SW, Aaronson SA. Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol 2003;23:857685.
  • 16
    Lu YS, Chen DR, Tseng LM, Yeh DC, Chen ST, Hsieh CM et al. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. Cancer Chemother Pharmacol 2011;67:125763.
  • 17
    Velentzis LS, Keshtgar MR, Woodside JV, Leathem AH, Titcomb A, Perkins KA et al. Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study. Breast Cancer Res Treat 2011;128:47382.
  • 18
    Sotgia F, Martinez-Outschoorn UE, Lisanti MP. Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? BMC Med 2011;9:62.
  • 19
    Katiyar S, Mukhtar H. Tea in chemoprevention of cancer. Int J Oncol 1996;8:22138.
  • 20
    Khan N, Afaq F, Mukhtar H. Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis 2007;28:2339.
  • 21
    Hara Y. Tea catechins and their applications as supplements and pharmaceutics. Pharmacol Res 2011;64:1004.
  • 22
    Sadava D, Whitlock E, Kane SE. The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem Biophys Res Commun 2007;360:2337.
  • 23
    Thangapazham RL, Passi N, Maheshwari RK. Green tea polyphenol and epigallocatechingallate induce apoptosis and inhibit invasion in human breast cancer cells. Cancer Biol Ther 2007;6:193843.
  • 24
    Yamamoto T, Staples J, Wataha J, Lewis J, Lockwood P, Schoenlein P et al. Protective effects of EGCG on salivary gland cells treated with gamma-radiation or cis-platinum(II)diammine dichloride. Anticancer Res 2004;24:306573.
  • 25
    Chan MM, Soprano KJ, Weinstein K, Fong D. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility. J Cell Physiol 2006;207:38996.
  • 26
    Gotoa T, Yoshidab Y, Kisob M, Nagashimaa H. Simultaneous analysis of individual catechins and caffeine in green tea. J Chromatogr A 1996;749:2959.
  • 27
    Chou TC, Talalay P. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:2755.
  • 28
    Uchiumi T, Knag D. Cisplatin sensitivity transcriptional factor and mitochondrial DNA maintenance protein. Rinsho Byori 2009;57:97886.
  • 29
    Li M, Balamuthusamy S, Khan AM, Maderdrut JL, Simon EE, Batuman V. Pituitary adenylatecyclase-activating polypeptide prevents cisplatin-induced renal failure. J Mol Neurosci 2011;43:5866.
  • 30
    Louie B, Rajamahanty S, Pyo P, Choudhury M, Konno S. Mode of cytotoxic action of nephrotoxic agents: oxidative stress and glutathione-dependent enzyme. BJU Int 2010;105:2648.
  • 31
    Pourahmad J, Hosseini MJ, Eskandari MR, Shekarabi SM, Daraei B. Mitochondrial/lysosomal toxic cross-talk plays a key role in cisplatin nephrotoxicity. Xenobiotica 2010;40:76371.
  • 32
    Il'yasova D, Kennedy K, Spasojevic I, Wang F, Tolun AA, Base K et al. Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat 2011;125:5839.
  • 33
    Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996;10:243851.
  • 34
    Chari NS, Pinaire NL, Thorpe L, Medeiros LJ, Routbort MJ, McDonnell TJ. The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death. Apoptosis 2009;14:33647.
  • 35
    Menendez D, Inga A, Resnick MA. Potentiating the p53 network. Discov Med 2011;10:94100.
  • 36
    Polyak K, Xia Y, Zweier JL, Kinzler KW. Vogelstein B.A model for p53-induced apoptosis. Nature 1997;389:3005.
  • 37
    Basu A, Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids 2011;8:2010.
  • 38
    Cai J, Jones DP. Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss. J Biol Chem 1998;273:114014.
  • 39
    Drisko JA, Chapman J, Hunter VJ. The use of antioxidant therapies during chemotherapy. Gynecol Oncol 2003;88:4349.
  • 40
    Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008;68:80318.
  • 41
    Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003;21:92731.
  • 42
    Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 2004;40:171323.
  • 43
    Suhail N, Bilal N, Khan HY, Hasan S, Sharma S, Khan F et al. Effect of vitamins C and E on antioxidant status of breast-cancer patients undergoing chemotherapy. J Clin Pharm Ther 2012;37:226.
  • 44
    Greenlee H, Kwan ML, Kushi LH, Song J, Castillo A, Weltzien E et al. Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. Cancer 2012;15:118.
  • 45
    Farabegoli F, Papi A, Orlandi M. (−)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci Rep 2011;31:99108.
  • 46
    Burns TF, El-Deiry WS. The p53 pathway and apoptosis. J Cell Physiol 1999;181:2319.
  • 47
    Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. Oncogene 2004;23:293449.
  • 48
    Adwankar M, Banerji A, Ghosh S. Differential response of retinoic acid pretreated human synovial sarcoma cell line to anticancer drugs. Tumoriogenesis 1991;7:3914.
  • 49
    Sadzuka Y, Sugiyama T, Hirota S. Modulation of cancer chemotherapy by green tea. Clin Cancer Res 1998;4:1536.
  • 50
    Ahmad N, Cheng P, Mukhtar H. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem Biophys Res Commun 2000;275:32834.
  • 51
    Van Cruchten S, Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002;31:21423.
  • 52
    Smolewski P, Grabarek J, Halicka HD, Darzynkiewicz Z. Assay of caspase activation in situ combined with probing plasma membrane integrity to detect three distinct stages of apoptosis. J Immunol Methods 2002;265:11121.
  • 53
    Michalak E, Villunger A, Erlacher M, Strasser A. Death squads enlisted by the tumour suppressor p53. Biochem Biophys Res Commun 2005;331:78698.